-
公开(公告)号：US20150057224A1
公开(公告)日：2015-02-26
申请号：US14218448
申请日：2014-03-18
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/0043 , A61K9/19 , A61M5/20 , A61M5/284 , A61M5/31533 , A61M5/3155 , A61M2205/583 , A61M2205/6063
摘要： A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonodotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug.
摘要翻译： 为了治疗慢性疼痛或其他中枢致敏后遗症，促性腺激素以惊人的有效的狭窄范围施用。 在一个方面，接受者被提供有至少一种人绒毛膜促性腺激素（uHCG和/或rHCG），药物活性HCG类似物和HCG或类似物的药物活性代谢物，其剂量选择为提供或相当于 HCG的120IU /天和170IU /天之间的人皮下剂量，更优选在140IU /天和160IU /天的HCG之间。 还描述了一种试剂盒，其包括HCG相关药物的供应，递送装置和识别慢性疼痛或中枢致敏作为药物的指示的标签。
-
公开(公告)号：US20150290293A1
公开(公告)日：2015-10-15
申请号：US14539940
申请日：2014-11-12
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0056 , A61K9/20 , A61M5/20 , A61M5/284 , A61M5/31533 , A61M2205/583 , A61M2205/6063
摘要： A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide an amount therapeutically bioequivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A combination product is also described, which includes a supply of the HCG-related drug, a delivery device, and a conversion scale for therapeutic bioequivalence that identifies the specific amount and route of administration for chronic pain or central sensitization as an indication of the drug.
摘要翻译： 为了治疗慢性疼痛或其他中枢致敏后遗症，促性腺激素以惊人的有效的狭窄范围施用。 在一个方面，向受体提供至少一种人绒毛膜促性腺激素（uHCG和/或rHCG），药物活性HCG类似物和HCG或类似物的药物活性代谢物，其剂量选择为提供治疗生物等效量 HCG的120IU /天和170IU /天之间的人皮下剂量，更优选在140IU /天和160IU /天的HCG之间。 还描述了组合产品，其包括HCG相关药物的供应，递送装置和用于治疗生物等效性的转化标准，其识别用于慢性疼痛或中枢敏化的特定量和给药途径作为药物的指示 。
-
公开(公告)号：US20170224782A1
公开(公告)日：2017-08-10
申请号：US15268979
申请日：2016-09-19
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/08 , A61K9/19
摘要： Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.
-
公开(公告)号：US20150290292A1
公开(公告)日：2015-10-15
申请号：US14436172
申请日：2013-10-18
申请人： NEURALIGHT HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/08 , A61K9/19
摘要： Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.
摘要翻译： 抑郁症和PTSD通过以相当于50-200IU，优选120-170IU，更优选140-170IU的皮下剂量的量施用hCG或hCG类似物或hCG或hCG类似物的前药或代谢物来治疗 -160 IU，每天hCG。
-
公开(公告)号：US20130196914A1
公开(公告)日：2013-08-01
申请号：US13633739
申请日：2012-10-02
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/0043 , A61K9/19 , A61M5/20 , A61M5/284 , A61M5/31533 , A61M5/3155 , A61M2205/583 , A61M2205/6063
摘要： A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug.
摘要翻译： 为了治疗慢性疼痛或其他中枢致敏后遗症，促性腺激素以惊人的有效的狭窄范围施用。 在一个方面，接受者被提供有至少一种人绒毛膜促性腺激素（uHCG和/或rHCG），药物活性HCG类似物和HCG或类似物的药物活性代谢物，其剂量选择为提供或相当于 HCG的120IU /天和170IU /天之间的人皮下剂量，更优选在140IU /天和160IU /天的HCG之间。 还描述了一种试剂盒，其包括HCG相关药物的供应，递送装置和识别慢性疼痛或中枢致敏作为药物的指示的标签。
-
公开(公告)号：US20190192633A1
公开(公告)日：2019-06-27
申请号：US16114002
申请日：2018-08-27
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0019 , A61K9/08 , A61K9/19
摘要： Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.
-
公开(公告)号：US20160339083A1
公开(公告)日：2016-11-24
申请号：US15225494
申请日：2016-08-01
申请人： Neuralight HD, LLC
CPC分类号： A61K38/24 , A61K9/0056 , A61K9/20 , A61M5/20 , A61M5/284 , A61M5/31533 , A61M2205/583 , A61M2205/6063
摘要： A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide an amount therapeutically bioequivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A combination product is also described, which includes a supply of the HCG-related drug, a delivery device, and a conversion scale for therapeutic bioequivalence that identifies the specific amount and route of administration for chronic pain or central sensitization as an indication of the drug.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
